Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Factor Xa Inhibitor [EPC]

Known as: Factor 10a Inhibitor, Activated Factor X Inhibitor, Activated Factor 10 Inhibitor 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract Essentials The value of thrombin generation assay (TGA) in monitoring direct oral anticoagulants (DOAC) is not well… Expand
Is this relevant?
2016
2016
The majority of embolisms associated with atrial fibrillation (AF) are from the left atrial appendage (LAA). To treat the… Expand
Is this relevant?
2015
2015
PurposeWe report on a 72-year-old male patient who developed a nontraumatic spinal subdural hematoma (SSDH) during rivaroxaban… Expand
  • figure 2
  • figure 1
Is this relevant?
2015
2015
The oral Factor Xa inhibitor rivaroxaban (Xarelto) has been the pharmacologic agent used for venous thromboembolism (VTE… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
OBJECTIVES The aim of this study was to determine the risk of major clinical and thromboembolic events after cardioversion for… Expand
  • table 1
  • table 2
Is this relevant?
2014
2014
Edoxaban, an oral direct factor Xa inhibitor, has proven antithrombotic efficacy. In a multicenter, phase II study, 264 total hip… Expand
  • table 1
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
OBJECTIVES The aim of this study was to determine if rivaroxaban is associated with a reduction in stent thrombosis among… Expand
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
2013
2013
BACKGROUND Accelerated vascular calcification and increased risk of calciphylaxis can be a reason to restrict the use of vitamin… Expand
  • table 1
  • table 2
Is this relevant?
2013
2013
Objectives: To determine the risk of major clinical and thromboembolic events after cardioversion for atrial fibrillation in… Expand
  • table 1
  • table 2
Is this relevant?
2013
2013
Background. Darexaban (YM150) is a potent direct factor Xa (FXa) inhibitor developed for the prophylaxis of venous and arterial… Expand
Is this relevant?